Chronic Lymphocytic Leukemia Minimum Residual Disease by Flow Cytometry
Also known as: CLL MRD
Use
This test is used to enumerate and characterize chronic lymphocytic leukemia cells (CD5+ monoclonal B-cells) in patients with a previously established diagnosis of CLL. It is designed to monitor disease status in known cases of CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) and provides valuable information on the presence or absence of residual leukemia cells. It is essential for assessing treatment response and disease progression in CLL patients.
Special Instructions
If no prior flow immunophenotyping has been performed, it is recommended to order Leukemia/Lymphoma Phenotyping Evaluation by Flow Cytometry (3001780). This test is not New York state approved due to short specimen stability. It is recommended that samples be submitted directly to a New York state-approved laboratory.
Limitations
The assay is limited to monitoring disease status in known cases of CLL/SLL and cannot be used to monitor or diagnose other B-cell lymphoproliferative disorders. The limit of detection of this assay is estimated to be 0.0042%. The test requires intact cellular specimens and should be received within 24 hours of collection for optimal cell viability.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 45266-4
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
green (sodium heparin), lavender (K2EDTA)
Storage Instructions
Room temperature. Also acceptable: Refrigerated. Specimen should be received within 24 hours of collection for optimal cell viability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |